NIMML Institute and NImmune Biopharma Partner to Advance Precision Medicine Research for Autoimmune Diseases
NIMML’s TITAN-X advanced computational modeling, bioinformatics and A.I. platform will be used to accelerate biomarker-driven clinical development of NImmune’s LANCL immunoregulatory drug pipeline
NIMML to receive up to $15 million in R&D funding for the precision medicine collaboration for rapidly advancing NImmune’s expansible drug pipeline
Blacksburg, VA., May 3, 2023 - The NIMML Institute(“NIMML”), a 501 (c)(3) nonprofit public charity organization dedicated to the discovery of novel immune-mediated precision medicines, today announced a research collaboration with NImmune Biopharma (“NImmune”), a late-clinical-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics. The collaboration will enable NImmune to access NIMML’s TITAN-X advanced computational modeling, bioinformatics and A.I. platform to accelerate biomarker-driven clinical development of its LANCL immunoregulatory drug pipeline.
Through this collaboration, NIMML and NImmune will work together to advance the clinical development of NImmune’s LANCL immunoregulatory therapeutic pipeline by identifying and validating therapeutically relevant gene clusters as biomarkers of response to treatment in blood and tissue biopsies. NIMML will utilize its proprietary TITAN-X drug development platform, as well as its industry-leading advanced computational modeling, A.I., and bioinformatics capabilities, to implement biomarker-driven approaches in NImmune’s upcoming clinical trials.
“Our collaboration with NImmune is a critical step in furthering our mission to discover novel immune-mediated precision medicines that can effectively and safely address a range of autoimmune diseases,” said Dr. David Moore, a NIMML Institute Board member and professor emeritus at Virginia Tech. “We are thrilled to work alongside NImmune, whose interests and goals closely align with ours, to advance our understanding of the underlying immunological mechanisms that fuel autoimmune diseases and develop safer and more effective therapeutics”.
Under the terms of the agreement, NIMML will receive up to $15 million in research and development funding from NImmune for costs associated with the precision medicine collaboration. NImmune will be solely responsible for the further development and commercialization of any biomarker-driven therapeutics that are being developed using NIMML’s TITAN-X platform. As part of the strategic relationship, NIMML will be eligible to receive future payments in regulatory and commercial milestones, as well as tiered single-digit royalties on global product sales for NImmune’s therapeutic pipeline.
“Following the successful launch of NImmune in March, this R&D collaboration between the NIMML Institute and NImmune broadly strengthens our precision immunology capabilities for developing safer and more effective immunoregulatory therapeutics that address the unmet clinical needs of patients with autoimmune diseases,” said Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune and Founding Director of NIMML. “This strategic partnership will accelerate the clinical testing and validation of therapeutically relevant gene clusters as biomarkers of response to treatment for omilancor, NIM-1324 and other product candidates in blood and tissue biopsies to determine which patients are most likely to benefit from the LANCL medications and, just as importantly, which are not.”
This collaboration represents a significant step forward in the development of novel immune-mediated precision medicines that can improve patient outcomes and quality of life toward NDA and commercialization.
NImmune Biopharma’s press release can be found here.
The NIMML Institute is a 501 (c) (3) non-profit foundation focused on applying transdisciplinary, team-science approaches to precision medicine. The NIMML Institute team leads numerous large-scale transdisciplinary projects and is dedicated to solving important societal problems through precision medicine by combining the expertise of immunologists, computational biologists, toxicologists, computational modelers, translational and clinical researchers, and molecular biologists. The Institute is headquartered in Blacksburg, VA. For more information, please visit www.nimml.org or contact email@example.com.
About NImmune Biopharma
NImmune is a late-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by a discovery platform that utilizes advanced computational modeling, A.I. and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. The lead product candidate from NImmune’s discovery platform is omilancor, a wholly-owned Phase 3-ready oral, once-daily, gut-restricted, first-in-class immunoregulatory therapeutic targeting LANCL2 for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2H’23. Phase 2 proof-of-concept data for omilancor show potential best in class efficacy and safety. For more information, please visit www.NIMMUNEBIO.COM or contact firstname.lastname@example.org.